Yolanda Piña

851 total citations
62 papers, 629 citations indexed

About

Yolanda Piña is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Ophthalmology. According to data from OpenAlex, Yolanda Piña has authored 62 papers receiving a total of 629 indexed citations (citations by other indexed papers that have themselves been cited), including 32 papers in Oncology, 30 papers in Pulmonary and Respiratory Medicine and 22 papers in Ophthalmology. Recurrent topics in Yolanda Piña's work include Brain Metastases and Treatment (29 papers), Glioma Diagnosis and Treatment (20 papers) and Ocular Oncology and Treatments (16 papers). Yolanda Piña is often cited by papers focused on Brain Metastases and Treatment (29 papers), Glioma Diagnosis and Treatment (20 papers) and Ocular Oncology and Treatments (16 papers). Yolanda Piña collaborates with scholars based in United States, Spain and Egypt. Yolanda Piña's co-authors include Diego G. Espinosa‐Heidmann, Scott W. Cousins, Alejandro Caicedo, Timothy G. Murray, Eleut P. Hernandez, William J. Feuer, Théodore J. Lampidis, Colleen M. Cebulla, Peter Forsyth and Karl G. Csaky and has published in prestigious journals such as Journal of Clinical Oncology, SHILAP Revista de lepidopterología and PLoS ONE.

In The Last Decade

Yolanda Piña

52 papers receiving 614 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Yolanda Piña United States 13 312 255 134 127 117 62 629
Nilanjana Sengupta United States 9 326 1.0× 425 1.7× 69 0.5× 54 0.4× 200 1.7× 19 669
Hannele Uusitalo‐Järvinen Finland 16 295 0.9× 288 1.1× 96 0.7× 28 0.2× 193 1.6× 36 663
Ri-ichiro Kohno Japan 13 221 0.7× 439 1.7× 67 0.5× 107 0.8× 150 1.3× 21 700
DT SHIMA United States 5 229 0.7× 325 1.3× 66 0.5× 64 0.5× 142 1.2× 5 574
Malinda L. Butz United States 12 164 0.5× 308 1.2× 204 1.5× 267 2.1× 272 2.3× 17 845
Fumihito Hikage Japan 16 262 0.8× 366 1.4× 96 0.7× 136 1.1× 159 1.4× 53 752
Alecia Cutler United States 8 128 0.4× 148 0.6× 80 0.6× 55 0.4× 95 0.8× 14 345
Maria-Luz Alvarez-Gonzalez Belgium 6 272 0.9× 402 1.6× 223 1.7× 40 0.3× 84 0.7× 7 655
Esther J. Kuiper Netherlands 8 295 0.9× 383 1.5× 45 0.3× 22 0.2× 216 1.8× 11 661

Countries citing papers authored by Yolanda Piña

Since Specialization
Citations

This map shows the geographic impact of Yolanda Piña's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Yolanda Piña with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Yolanda Piña more than expected).

Fields of papers citing papers by Yolanda Piña

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Yolanda Piña. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Yolanda Piña. The network helps show where Yolanda Piña may publish in the future.

Co-authorship network of co-authors of Yolanda Piña

This figure shows the co-authorship network connecting the top 25 collaborators of Yolanda Piña. A scholar is included among the top collaborators of Yolanda Piña based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Yolanda Piña. Yolanda Piña is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Piña, Yolanda, Vincent Law, Solmaz Sahebjam, et al.. (2025). Phase IB study of Avelumab and whole brain radiotherapy in patients with leptomeningeal disease from solid tumors: Results and molecular analyses. Neuro-Oncology. 27(12). 3237–3249.
2.
Piña, Yolanda, et al.. (2024). Preparación para inclusión en lista de espera para trasplante renal. 1 indexed citations
3.
Piña, Yolanda, et al.. (2024). ANGI-07. A CASE OF HYPERBARIC OXYGEN USED AS A TREATMENT MODALITY FOR ANAPLASTIC ASTROCYTOMA. Neuro-Oncology. 26(Supplement_8). viii17–viii17.
4.
Cao, Biwei, Youngchul Kim, Peter Forsyth, et al.. (2024). Factors associated with overall survival in breast cancer patients with leptomeningeal disease (LMD): a single institutional retrospective review. Breast Cancer Research. 26(1). 55–55. 5 indexed citations
5.
Ahmed, Kamran A., Priya Kumthekar, Yolanda Piña, et al.. (2024). Radiation Therapy Followed by Intrathecal Trastuzumab-Pertuzumab for ERBB2-Positive Breast Leptomeningeal Disease. JAMA Oncology. 10(7). 984–984. 2 indexed citations
6.
Piña, Yolanda, et al.. (2024). NCMP-18. A CASE OF METASTATIC GLIOBLASTOMA MULTIFORME. Neuro-Oncology. 26(Supplement_8). viii220–viii220.
7.
Sahebjam, Solmaz, Nam Tran, Rachid Baz, et al.. (2022). Leukoencephalopathy During Daratumumab-Based Therapy: A Case Series of Two Patients with Multiple Myeloma. OncoTargets and Therapy. Volume 15. 953–962. 4 indexed citations
8.
Piña, Yolanda, et al.. (2022). Advances in Diagnosis and Treatment for Leptomeningeal Disease in Melanoma. Current Oncology Reports. 24(1). 43–54. 5 indexed citations
9.
Liu, James K., Junmin Whiting, Krupal Patel, et al.. (2022). Patient satisfaction and cost savings analysis of the telemedicine program within a neuro-oncology department. Journal of Neuro-Oncology. 160(2). 517–525. 6 indexed citations
10.
Piña, Yolanda, et al.. (2021). Rituximab for Immune Checkpoint Inhibitor Myasthenia Gravis. Cureus. 13(7). e16337–e16337. 11 indexed citations
11.
Piña, Yolanda, Michael Fusco, Robert Macaulay, et al.. (2019). Using personalized medicine in gliomas: a genomic approach to diagnosis and overcoming treatment resistance in a case with pleomorphic xanthoastrocytoma. Journal of Neurology. 267(3). 783–790. 7 indexed citations
12.
Houston, Samuel K., Yolanda Piña, Colleen M. Cebulla, et al.. (2011). Novel retinoblastoma treatment avoids chemotherapy: the effect of optimally timed combination therapy with angiogenic and glycolytic inhibitors on LHBETATAG retinoblastoma tumors. Clinical ophthalmology. 5. 129–129. 10 indexed citations
13.
Piña, Yolanda, Samuel K. Houston, William K. Scott, et al.. (2010). Retinoblastoma Molecular Genomics: Regional Differences in the Molecular Genomics Expression Following Treatment With 2-Deoxy-D-Glucose in LHBETATAG Retinal Tumors. Investigative Ophthalmology & Visual Science. 51(13). 1576–1576. 1 indexed citations
14.
Houston, S. K., et al.. (2010). Intraoperative Spectral Domain Optical Coherence Tomography (SD-OCT) Imaging of Complex Pediatric Retinal Disease. Investigative Ophthalmology & Visual Science. 51(13). 3861–3861. 1 indexed citations
15.
Merchan, Jaime R., Metin Kurtoğlu, Yolanda Piña, et al.. (2010). Antiangiogenic Activity of 2-Deoxy-D-Glucose. PLoS ONE. 5(10). e13699–e13699. 94 indexed citations
16.
17.
Piña, Yolanda, et al.. (2008). Tumor Infiltrating Lymphocytes in Retinal Tumors From LHBETATAG mice. Investigative Ophthalmology & Visual Science. 49(13). 75–75. 1 indexed citations
18.
Murray, Timothy G., et al.. (2007). Targeting the Tumor Microenvironment as a Therapeutic Strategy for Retinoblastoma. Investigative Ophthalmology & Visual Science. 48(13). 1585–1585. 1 indexed citations
19.
Pereira‐Simon, Simone, et al.. (2005). Cigarette Smoke Increases Severity of Experimental Choroidal Neovascularization (CNV): Role of Inflammation. Investigative Ophthalmology & Visual Science. 46(13). 3507–3507. 3 indexed citations
20.
Caicedo, Alejandro, et al.. (2004). Aged bone marrow transfers age–related pathology into young recipients in experimental choroidal neovascularization (CNV).. Investigative Ophthalmology & Visual Science. 45(13). 1853–1853. 2 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Nilanjana Sengupta Breakdown of academic impact, for papers by Hannele Uusitalo‐Järvinen Breakdown of academic impact, for papers by Ri-ichiro Kohno Breakdown of academic impact, for papers by DT SHIMA Breakdown of academic impact, for papers by Malinda L. Butz Breakdown of academic impact, for papers by Fumihito Hikage Breakdown of academic impact, for papers by Alecia Cutler Breakdown of academic impact, for papers by Maria-Luz Alvarez-Gonzalez Breakdown of academic impact, for papers by Esther J. Kuiper
Rankless by CCL
2026